BUB1 an Overexpressed Kinase in Sarcoma: Finding New Target Therapy for Osteosarcoma, Liposarcoma, Synovial Sarcoma, and Leiomyosarcoma

Sarcomas are heterogeneous mesenchymal tumors, and their pharmacological treatment remains challenging due to the high toxicity and poor efficacy of current therapies. This study aimed to identify common overexpressed kinases in the four most frequent sarcoma subtypes to establish novel therapeutic...

Full description

Saved in:
Bibliographic Details
Main Authors: Mercedes Olvera-Valencia, Fernando Luna-Maldonado, Joselyn Juarez-Reyes, Alejandro Lopez-Saavedra, Jossimar Coronel-Hernandez, Oliver Millan-Catalan, Daniel Guzman-Gomez, Frida Rodríguez-Izquierdo, Luis A. Herrera, David Francisco Cantú-De León, Carlos Perez-Plasencia, Eloy-Andres Pérez-Yepez
Format: Article
Language:English
Published: MDPI AG 2025-07-01
Series:Biomolecules
Subjects:
Online Access:https://www.mdpi.com/2218-273X/15/7/1046
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850078207911395328
author Mercedes Olvera-Valencia
Fernando Luna-Maldonado
Joselyn Juarez-Reyes
Alejandro Lopez-Saavedra
Jossimar Coronel-Hernandez
Oliver Millan-Catalan
Daniel Guzman-Gomez
Frida Rodríguez-Izquierdo
Luis A. Herrera
David Francisco Cantú-De León
Carlos Perez-Plasencia
Eloy-Andres Pérez-Yepez
author_facet Mercedes Olvera-Valencia
Fernando Luna-Maldonado
Joselyn Juarez-Reyes
Alejandro Lopez-Saavedra
Jossimar Coronel-Hernandez
Oliver Millan-Catalan
Daniel Guzman-Gomez
Frida Rodríguez-Izquierdo
Luis A. Herrera
David Francisco Cantú-De León
Carlos Perez-Plasencia
Eloy-Andres Pérez-Yepez
author_sort Mercedes Olvera-Valencia
collection DOAJ
description Sarcomas are heterogeneous mesenchymal tumors, and their pharmacological treatment remains challenging due to the high toxicity and poor efficacy of current therapies. This study aimed to identify common overexpressed kinases in the four most frequent sarcoma subtypes to establish novel therapeutic targets. A bioinformatics approach using patient-derived gene expression data sets identified overexpressed kinases shared across these sarcoma types. Later, <i>BUB1</i> was determined as the kinase consistently overexpressed across the osteosarcoma, liposarcoma, leiomyosarcoma, and synovial sarcoma. Moreover, the role of this kinase was further validated through molecular and functional assays, including pharmacological inhibition in cell lines derived from the four sarcoma subtypes. BUB1 inhibition reduced the phosphorylation of AKT and H2A proteins, precluded cell proliferation, and inhibited colony formation in sarcoma cells. Finally, overall survival analysis highlighted a strong correlation between high <i>BUB1</i> expression and poorer survival rates in sarcoma patients. Altogether, these findings underscore the potential of BUB1 as a therapeutic target and prognostic marker in sarcomas. Targeted inhibition of BUB1 may provide a novel strategy to reduce tumor growth and improve outcomes for patients with bone and soft tissue sarcomas.
format Article
id doaj-art-d6c0a20bc9d94a7d98bcad95054a6530
institution DOAJ
issn 2218-273X
language English
publishDate 2025-07-01
publisher MDPI AG
record_format Article
series Biomolecules
spelling doaj-art-d6c0a20bc9d94a7d98bcad95054a65302025-08-20T02:45:37ZengMDPI AGBiomolecules2218-273X2025-07-01157104610.3390/biom15071046BUB1 an Overexpressed Kinase in Sarcoma: Finding New Target Therapy for Osteosarcoma, Liposarcoma, Synovial Sarcoma, and LeiomyosarcomaMercedes Olvera-Valencia0Fernando Luna-Maldonado1Joselyn Juarez-Reyes2Alejandro Lopez-Saavedra3Jossimar Coronel-Hernandez4Oliver Millan-Catalan5Daniel Guzman-Gomez6Frida Rodríguez-Izquierdo7Luis A. Herrera8David Francisco Cantú-De León9Carlos Perez-Plasencia10Eloy-Andres Pérez-Yepez11Programa Institucional de Biomedicina Molecular, Escuela Nacional de Medicina y Homeopatía del IPN, Guillermo Massieu Helguera #239 Fracc. La escalera, Ticoman 07320, Ciudad de Mexico, MexicoUnidad de Investigación Biomédica en Cáncer, Insituto de Investigaciones Biomédicas-Universidad Nacional Autónoma de México, Instituto Nacional de Cancerología, Mexico City 14080, MexicoLaboratorio de Genómica, Instituto Nacional de Cancerología, San Fernando 22. Col. Sección XVI, Tlalpan 14080, Ciudad de Mexico, MexicoAdvanced Microscopy Applications Unit (ADMIRA)-Instituto Nacional de Cancerología, San Fernando 22. Col. Sección XVI, Tlalpan 14080, Ciudad de Mexico, MexicoLaboratorio de Genómica, Instituto Nacional de Cancerología, San Fernando 22. Col. Sección XVI, Tlalpan 14080, Ciudad de Mexico, MexicoLaboratorio de Genómica, Instituto Nacional de Cancerología, San Fernando 22. Col. Sección XVI, Tlalpan 14080, Ciudad de Mexico, MexicoLADISER de Inmunología y Biología Molecular, Facultad de Ciencias Químicas, Universidad Veracruzana (UV), Prolongación de Oriente 6 #1009, Colonia Rafael Alvarado, Orizaba 94340, Veracruz, MexicoLaboratorio de Genómica, Instituto Nacional de Cancerología, San Fernando 22. Col. Sección XVI, Tlalpan 14080, Ciudad de Mexico, MexicoUnidad de Investigación Biomédica en Cáncer, Insituto de Investigaciones Biomédicas-Universidad Nacional Autónoma de México, Instituto Nacional de Cancerología, Mexico City 14080, MexicoClinical Research, Instituto Nacional de Cancerologia, San Fernando 22. Col. Sección XVI, Tlalpan, Ciudad de Mexico 14080, MexicoLaboratorio de Genómica, Instituto Nacional de Cancerología, San Fernando 22. Col. Sección XVI, Tlalpan 14080, Ciudad de Mexico, MexicoLaboratorio de Genómica, Instituto Nacional de Cancerología, San Fernando 22. Col. Sección XVI, Tlalpan 14080, Ciudad de Mexico, MexicoSarcomas are heterogeneous mesenchymal tumors, and their pharmacological treatment remains challenging due to the high toxicity and poor efficacy of current therapies. This study aimed to identify common overexpressed kinases in the four most frequent sarcoma subtypes to establish novel therapeutic targets. A bioinformatics approach using patient-derived gene expression data sets identified overexpressed kinases shared across these sarcoma types. Later, <i>BUB1</i> was determined as the kinase consistently overexpressed across the osteosarcoma, liposarcoma, leiomyosarcoma, and synovial sarcoma. Moreover, the role of this kinase was further validated through molecular and functional assays, including pharmacological inhibition in cell lines derived from the four sarcoma subtypes. BUB1 inhibition reduced the phosphorylation of AKT and H2A proteins, precluded cell proliferation, and inhibited colony formation in sarcoma cells. Finally, overall survival analysis highlighted a strong correlation between high <i>BUB1</i> expression and poorer survival rates in sarcoma patients. Altogether, these findings underscore the potential of BUB1 as a therapeutic target and prognostic marker in sarcomas. Targeted inhibition of BUB1 may provide a novel strategy to reduce tumor growth and improve outcomes for patients with bone and soft tissue sarcomas.https://www.mdpi.com/2218-273X/15/7/1046sarcomakinasesbone sarcomatherapeutic targetsoft tissue sarcomas
spellingShingle Mercedes Olvera-Valencia
Fernando Luna-Maldonado
Joselyn Juarez-Reyes
Alejandro Lopez-Saavedra
Jossimar Coronel-Hernandez
Oliver Millan-Catalan
Daniel Guzman-Gomez
Frida Rodríguez-Izquierdo
Luis A. Herrera
David Francisco Cantú-De León
Carlos Perez-Plasencia
Eloy-Andres Pérez-Yepez
BUB1 an Overexpressed Kinase in Sarcoma: Finding New Target Therapy for Osteosarcoma, Liposarcoma, Synovial Sarcoma, and Leiomyosarcoma
Biomolecules
sarcoma
kinases
bone sarcoma
therapeutic target
soft tissue sarcomas
title BUB1 an Overexpressed Kinase in Sarcoma: Finding New Target Therapy for Osteosarcoma, Liposarcoma, Synovial Sarcoma, and Leiomyosarcoma
title_full BUB1 an Overexpressed Kinase in Sarcoma: Finding New Target Therapy for Osteosarcoma, Liposarcoma, Synovial Sarcoma, and Leiomyosarcoma
title_fullStr BUB1 an Overexpressed Kinase in Sarcoma: Finding New Target Therapy for Osteosarcoma, Liposarcoma, Synovial Sarcoma, and Leiomyosarcoma
title_full_unstemmed BUB1 an Overexpressed Kinase in Sarcoma: Finding New Target Therapy for Osteosarcoma, Liposarcoma, Synovial Sarcoma, and Leiomyosarcoma
title_short BUB1 an Overexpressed Kinase in Sarcoma: Finding New Target Therapy for Osteosarcoma, Liposarcoma, Synovial Sarcoma, and Leiomyosarcoma
title_sort bub1 an overexpressed kinase in sarcoma finding new target therapy for osteosarcoma liposarcoma synovial sarcoma and leiomyosarcoma
topic sarcoma
kinases
bone sarcoma
therapeutic target
soft tissue sarcomas
url https://www.mdpi.com/2218-273X/15/7/1046
work_keys_str_mv AT mercedesolveravalencia bub1anoverexpressedkinaseinsarcomafindingnewtargettherapyforosteosarcomaliposarcomasynovialsarcomaandleiomyosarcoma
AT fernandolunamaldonado bub1anoverexpressedkinaseinsarcomafindingnewtargettherapyforosteosarcomaliposarcomasynovialsarcomaandleiomyosarcoma
AT joselynjuarezreyes bub1anoverexpressedkinaseinsarcomafindingnewtargettherapyforosteosarcomaliposarcomasynovialsarcomaandleiomyosarcoma
AT alejandrolopezsaavedra bub1anoverexpressedkinaseinsarcomafindingnewtargettherapyforosteosarcomaliposarcomasynovialsarcomaandleiomyosarcoma
AT jossimarcoronelhernandez bub1anoverexpressedkinaseinsarcomafindingnewtargettherapyforosteosarcomaliposarcomasynovialsarcomaandleiomyosarcoma
AT olivermillancatalan bub1anoverexpressedkinaseinsarcomafindingnewtargettherapyforosteosarcomaliposarcomasynovialsarcomaandleiomyosarcoma
AT danielguzmangomez bub1anoverexpressedkinaseinsarcomafindingnewtargettherapyforosteosarcomaliposarcomasynovialsarcomaandleiomyosarcoma
AT fridarodriguezizquierdo bub1anoverexpressedkinaseinsarcomafindingnewtargettherapyforosteosarcomaliposarcomasynovialsarcomaandleiomyosarcoma
AT luisaherrera bub1anoverexpressedkinaseinsarcomafindingnewtargettherapyforosteosarcomaliposarcomasynovialsarcomaandleiomyosarcoma
AT davidfranciscocantudeleon bub1anoverexpressedkinaseinsarcomafindingnewtargettherapyforosteosarcomaliposarcomasynovialsarcomaandleiomyosarcoma
AT carlosperezplasencia bub1anoverexpressedkinaseinsarcomafindingnewtargettherapyforosteosarcomaliposarcomasynovialsarcomaandleiomyosarcoma
AT eloyandresperezyepez bub1anoverexpressedkinaseinsarcomafindingnewtargettherapyforosteosarcomaliposarcomasynovialsarcomaandleiomyosarcoma